Synopsis of recent research by authors named "Amber Woolfenden"
- Amber Woolfenden's research primarily focuses on developing novel therapies for ocular diseases, particularly targeting neovascular age-related macular degeneration (AMD) through various approaches, including topical delivery and oral administration of VEGFR-2 inhibitors.
- Her studies have successfully identified acrizanib, a small-molecule VEGFR-2 inhibitor, demonstrating its efficacy in rodent models with favorable pharmacokinetics, representing a potential alternative to the invasive intravitreal injections currently used for AMD treatment.
- Additionally, Woolfenden's work has investigated the role of CEP adducts in angiogenesis and the reliability of animal models in studying choroidal neovascularization, contributing valuable insights into the mechanisms behind ocular neovascular conditions.
